Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Part of the problem is, as obesity theorist and computational physiologist Edward Archer bluntly says, much of the “[nutrition] data is meaningless.” One of the things that the FDA should ...

The FDA on Friday said it approved Novo Nordisk’s popular weight-loss drug Wegovy to reduce the risk of severe heart issues in overweight or obese adults ... Holst Lange, head of development ...